Ozempic Injection: Administration, Sites, and Storage

Where the shot goes

The Ozempic label names three subcutaneous sites: the abdomen, the thigh or the upper arm [1]. The label's instruction on placement is rotation: use a different injection site each week when injecting in the same body region [1]. The Wegovy label reports similar semaglutide exposure after injection into the abdomen, thigh or upper arm [4].

Once a week, on the same day

The label describes Ozempic as given once weekly, on the same day each week, at any time of day, with or without meals [1].

The labeled sequence for glycemic control starts at 0.25 mg once weekly for 4 weeks (a starting dose, not a maintenance dose), moves to 0.5 mg, then to 1 mg after at least 4 weeks on 0.5 mg, then to 2 mg after at least 4 weeks on 1 mg [1]. For the kidney indication, the label moves to 1 mg after at least 4 weeks on 0.5 mg [1]. The maximum is 2 mg weekly [1].

If a dose is missed

The label says to give a missed dose within 5 days of the scheduled day; if more than 5 days have passed, skip it and resume the usual weekly day [1]. The label also allows the weekly dosing day to be changed, provided doses are more than 48 hours apart [1].

Before injecting

Inspect the solution. The label says to inspect Ozempic visually before use: it should appear clear and colorless, and it should not be used if particulate matter or coloration is seen [1].

Pen sharing. The label says Ozempic pens must never be shared between patients, even if the needle is changed, because pen sharing carries a risk of transmitting blood-borne pathogens [1].

Use with insulin. The label says to give Ozempic and insulin as separate injections and never to mix them; the two can go into the same body region, but the injections should not be adjacent [1].

Surgery or sedation. The label advises telling healthcare providers about planned surgeries or procedures, because pulmonary aspiration has been reported in people taking GLP-1 receptor agonists during general anesthesia or deep sedation [1].

Storage

FDA says injectable GLP-1 drugs require refrigeration as indicated in their package inserts [2]. FDA also says improper storage during shipping can affect a drug's quality, that it has received complaints of compounded GLP-1 drugs arriving warm or with inadequate ice packs, and that it recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration [2].

For multi-dose vials of sterile medications, which FDA notes compounded GLP-1 drugs may be dispensed in, FDA generally recommends use within 28 days after first use. It recommends discarding the vial at 28 days even if medication remains, and not continuing to use it even if the compounder's instructions allow a longer window [2]. FDA also recommends a new sterile needle and syringe for every dose, because reusing them can contaminate the medication [2].

Compounded semaglutide in vials

Ozempic comes as prefilled pens [3]. FDA says compounded GLP-1 medications may be dispensed in vials containing multiple doses for a patient to self-administer [2].

Compounded semaglutide is not FDA approved and is not reviewed for safety, effectiveness or quality before it is marketed [2]. FDA reports dosing errors with compounded injectable semaglutide, including patients measuring the wrong dose and clinicians miscalculating [2]. FDA also states that semaglutide sodium and semaglutide acetate salts are different active ingredients from the approved drug [2].

What the label warns about

Ozempic's label warns about acute pancreatitis and says to discontinue Ozempic if pancreatitis is suspected [1]. Its other warnings include acute gallbladder disease, serious hypersensitivity reactions including anaphylaxis and angioedema, acute kidney injury from volume depletion, severe gastrointestinal reactions, and hypoglycemia when used with insulin or a sulfonylurea [1].

In pooled placebo-controlled trials in type 2 diabetes, gastrointestinal reactions were reported by 15.3% of people on placebo, 32.7% on 0.5 mg and 36.4% on 1 mg; nausea by 6.1%, 15.8% and 20.3% respectively; and treatment was stopped for gastrointestinal reasons by 0.4%, 3.1% and 3.8% [1]. Most reports of nausea, vomiting and diarrhea occurred during dose escalation [1].

Ozempic's labeled indications are glycemic control in type 2 diabetes, cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease, and kidney outcomes in type 2 diabetes with chronic kidney disease [1]. Its label lists no weight-loss indication [1].